Skip to content

Advertisement

  • Oral presentation
  • Open Access

Equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis

  • 1,
  • 1,
  • 2,
  • 2,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of Cardiovascular Magnetic Resonance201012 (Suppl 1) :O16

https://doi.org/10.1186/1532-429X-12-S1-O16

  • Published:

Keywords

  • Continuous Infusion
  • Late Gadolinium Enhancement
  • Automate Image Analysis
  • Myocardial Biopsy
  • Technique Equilibrium

Introduction

Diffuse myocardial fibrosis (DMF) is a final endpoint in most cardiac diseases. It is missed by the late gadolinium enhancement technique. Currently, the only method to quantify DMF is biopsy, which has risk and is prone to sampling error.

Purpose

We have developed a new technique Equilibrium Contrast CMR (EQ-CMR) - the first clinically applicable, robust, noninvasive method to quantify DMF and show it to be accurate against the current gold-standard of surgical myocardial biopsy.

Methods

The three elements of EQ-CMR are: a bolus of extra-cellular Gd-DTPA contrast followed by continuous infusion to achieve equilibrium; a blood sample to measure blood volume of distribution, Vd(b) (one minus haematocrit); and CMR to measure pre and post equilibrium T1 (with heart rate correction). Vd(m) is calculated, reflecting DMF.

Equilibrium acquisition was optimized in 16 individuals and achieved by a combination of loading bolus and slow continuous infusion. The T1 measurement technique and heart rate correction was validated in phantoms against T1 relaxometry and then against blood [Gd-DTPA]. Clinical validation was in patients undergoing AVR for AS or myectomy in HCM (n = 18 and 8 respectively). The surgical biopsies were analyzed using fully automated image analysis (macros in ImageJ) for picro-sirius red fibrosis quantification on histology. The scan protocol is outlined in Figure 1.
Figure 1
Figure 1

Figure 1

Results

Equilibrium was achieved in all patients within 40 minutes. The second scan took 5 mins ± 42 secs (9 breath-holds). The mean histological fibrosis was 20.5% ± 11% in AS and 17.1% ± 7.4 in HCM (Figure 2). The total Gd-DTPA dose was 0.14 ± 0.001 mmol/kg. EQ-CMR Vd(m) correlated strongly with biopsy histological fibrosis: AS: r2 = 0.86, p < 0.001; HCM: r2 = 0.62, p < 0.02; combined r2 = 0.80, p < 0.001 (Figure 3).
Figure 2
Figure 2

Figure 2

Figure 3
Figure 3

Figure 3

Conclusion

We have developed and validated a new technique, EQ-CMR to measure diffuse myocardial fibrosis. It is a simple, reliable and clinically.

Authors’ Affiliations

(1)
The Heart Hospital, London, UK
(2)
Great Ormond Street Hospital, London, UK

Copyright

© Flett et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd.

Advertisement